umbrella
definit
requir
integr
bench
bedsid
approach
use
data
ongo
genom
proteom
profil
studi
larg
wellcharacter
asthma
populationssuch
current
euwid
ubiopr
studi
formal
unbias
biomark
predict
respiratori
diseas
outcom
feedback
improv
vitro
vivo
anim
model
human
studi
intern
consensu
report
diagnosi
treatment
asthma
defin
asthma
chronic
inflammatori
disord
airway
mani
cell
play
role
includ
mast
cell
eosinophil
suscept
individu
inflamm
caus
symptom
usual
associ
widespread
variabl
airflow
obstruct
often
revers
either
spontan
treatment
caus
associ
increas
airway
respons
varieti
stimuli
interact
featur
determin
clinic
manifest
sever
diseas
respons
treatment
featur
relat
best
measur
contribut
clinic
manifest
diseas
remain
unclear
age
diseas
onset
also
complic
understand
although
mani
share
featur
diagnosi
asthma
children
adult
also
import
differ
differenti
diagnosi
natur
histori
wheez
ill
abil
perform
certain
investig
influenc
age
accord
world
health
organ
million
peopl
around
globe
roughli
equival
popul
russian
feder
suffer
asthma
worldwid
death
asthma
reach
annual
overal
asthma
affect
popul
mani
develop
countri
one
studi
found
annual
estim
incid
physiciandiagnos
asthma
rang
per
person
risk
factor
incid
asthma
among
children
includ
male
gender
atop
sensit
parent
histori
asthma
earlylif
stressor
infect
obes
exposur
indoor
allergen
tobacco
smoke
outdoor
pollut
risk
factor
adultonset
asthma
includ
femal
sex
airway
hyperrespons
lifestyl
factor
workrel
exposur
exact
cost
asthma
care
difficult
determin
systemat
review
found
eight
nation
studi
report
nation
total
cost
total
cost
us
dollar
high
vari
wide
singapor
canada
switzerland
germani
unit
state
although
cost
asthma
care
vari
countri
estim
worldwid
number
disabilityadjust
life
year
dali
lost
asthma
million
per
year
worldwid
asthma
account
around
dali
lost
reflect
high
preval
sever
asthma
number
asthmacaus
lost
dali
similar
diabet
cirrhosi
liver
schizophrenia
cost
relat
factor
includ
asthma
control
demograph
medic
histori
dose
inhal
corticosteroid
ic
prescrib
improv
asthma
control
associ
decreas
cost
asthma
classic
caus
wheez
cough
chest
tight
breathless
dyspnoea
pattern
symptom
clue
diagnosi
episod
symptom
wors
night
earli
morn
respons
exercis
allergen
cold
air
exposur
take
aspirin
beta
blocker
suggest
asthma
moreov
symptom
reliev
bronchodil
point
toward
asthma
underli
caus
symptom
lower
probabl
asthma
includ
promin
dizzi
lightheaded
peripher
tingl
point
toward
dysfunct
breath
chronic
product
cough
absenc
wheez
breathless
like
bronchiectasi
repeatedli
normal
physic
examin
chest
symptomat
voic
disturb
symptom
cold
signific
smoke
histori
take
detail
patient
histori
record
spirometri
patient
symptomat
crucial
accur
classif
diseas
sever
differenti
diagnos
must
consid
make
diagnosi
asthma
outsid
scope
chapter
good
guid
clinic
diagnosi
manag
asthma
british
thorac
societi
asthma
guidelin
updat
regularli
avail
wwwbritthoracicorgukclinicalinform
asthma
trigger
asthma
symptom
includ
allergen
protein
deriv
among
other
hous
dust
mite
hdm
cat
dog
dander
cockroach
fungi
especi
aspergillu
fumigatu
numer
nonallerg
symptom
trigger
includ
weather
atmospher
chang
air
pollut
exercis
menstruat
emot
laughter
viral
infect
gastroesophag
reflux
rhiniti
variou
occup
caus
worsen
asthma
eg
weld
bake
paint
spray
asthma
symptom
often
overlap
allergi
includ
oral
allergi
syndrom
food
allergi
delin
caus
symptom
difficult
specif
aeroallergen
identifi
trigger
asthma
classic
tree
grass
pollen
cours
either
sublingu
subcutan
desensit
undertaken
reduc
symptom
exposur
specif
allergen
multipl
symptom
trigger
includ
allerg
nonallerg
mechan
exampl
includ
exposur
chemic
perfum
paint
bleach
plant
eg
ligustrum
vulgareprivet
hedg
salicyl
sulphit
multipl
factor
shown
either
directli
caus
worsen
symptom
asthma
list
box
factor
directli
relat
diseas
worsen
symptom
associ
frequent
exacerb
includ
dysfunct
breath
vocal
cord
dysfunct
psychosoci
problem
poor
adher
treatment
regim
form
asthma
recogn
among
occup
exerciseinduc
pregnancyrel
asthma
subdivis
somewhat
arbitrari
may
differ
caus
prognos
complex
exampl
occup
asthma
includ
trigger
igemedi
mechan
due
specif
agent
unclear
pathophysiolog
secondari
irrit
also
known
radsreact
airway
dysfunct
syndrom
underli
asthma
also
made
wors
occup
exposur
workaggrav
expert
regard
exerciseinduc
asthma
differ
diseas
albeit
one
result
similar
symptom
exerciseinduc
asthma
often
diagnos
differ
investig
includ
eucapn
voluntari
hyperventil
exercis
test
associ
certain
sport
swim
cross
countri
ski
particular
uniqu
pathophysiolog
directli
relat
damag
airway
epithelium
asthma
control
deterior
pregnanc
due
hormon
effect
physic
effect
gravid
uteru
diaphragm
respiratori
muscl
function
pregnanc
also
impact
treatment
decis
leukotrien
modifi
gener
contraind
health
fetu
well
mother
need
consid
poor
adher
probabl
biggest
singl
issu
affect
asthma
control
studi
shown
peopl
asthma
overreport
use
ic
one
studi
found
although
respond
said
use
inhal
actual
adher
ic
therapi
associ
lower
rate
death
wherea
increas
use
reliev
salbutamolbricanyl
medic
improv
symptom
treat
underli
airway
inflamm
associ
increas
mortal
report
entitl
evalu
scale
caus
cost
wast
medicin
report
dh
fund
nation
project
trueman
et
al
york
health
econom
consortium
univers
london
school
pharmaci
put
figur
possibl
cost
benefit
improv
asthma
treatment
adher
unit
kingdom
estim
result
net
benefit
associ
complianc
per
patient
reduct
expect
annual
treatment
cost
approxim
per
patient
per
year
base
asthma
point
preval
find
suggest
almost
million
asthmat
unit
kingdom
noncompli
intervent
avail
chang
behavior
partial
compliant
medicin
user
rais
percentag
report
estim
million
treatment
cost
save
could
realiz
unit
kingdom
alon
modest
target
doubl
current
complianc
rate
would
result
save
approxim
million
per
year
aim
asthma
treatment
improv
symptom
maintain
lung
function
prevent
exacerb
patient
perspect
simpl
aim
purpos
studi
design
treatment
trial
address
complex
diseas
process
accordingli
guidelin
specif
address
asthma
control
symptom
lung
function
sever
need
treatment
separ
current
global
initi
asthma
gina
guidelin
assess
level
control
base
daytim
symptom
limit
activ
nocturn
symptomsawaken
need
relieverrescu
treatment
lung
function
pef
fev
exacerb
treatment
step
defin
treatment
level
requir
maintain
asthma
control
tabl
patient
step
wellcontrol
asthma
requir
littl
treatment
patient
step
poorli
control
asthma
despit
four
five
differ
drug
step
approach
similar
use
british
thorac
societi
bt
guidelin
asthma
variabl
diseas
tempor
clinic
also
overlap
symptom
exacerb
overlap
subject
recent
consensu
document
defin
asthma
exacerb
event
character
chang
patient
previou
statu
sever
exacerb
event
requir
urgent
action
part
patient
physician
prevent
seriou
outcom
hospit
death
asthma
moder
asthma
exacerb
event
troublesom
patient
prompt
need
chang
treatment
identifi
outsid
patient
usual
rang
daytoday
asthma
variat
practic
definit
asthma
exacerb
probabl
episod
worsen
symptom
respond
increas
bronchodil
therapi
definit
employ
eleg
studi
time
cours
peak
flow
chang
purpos
clinic
studi
author
defin
exacerb
need
rescu
cours
system
corticosteroid
prednisoloneprednison
although
major
patient
asthma
treat
investig
primari
care
set
main
burden
asthma
due
sever
form
ie
step
exacerb
use
unit
kingdom
exampl
popul
million
asthma
respons
death
per
year
hospit
admiss
annual
expenditur
million
pharmaceut
cost
alon
recent
estim
patient
control
mildest
end
spectrum
british
thorac
societi
bt
guidelin
step
exacerb
would
cost
time
less
provid
packag
care
would
patient
worst
end
spectrum
bt
guidelin
step
exacerb
also
calcul
asthma
patient
respons
least
total
healthcar
burden
expens
individu
cost
icu
admiss
bt
level
due
lifethreaten
exacerb
us
half
asthma
suffer
asthma
attack
half
children
onethird
adult
miss
school
work
averag
children
miss
four
day
school
adult
miss
five
day
work
exacerb
pathogenesi
fulli
understood
although
research
focus
infect
agent
especi
viral
may
explan
asthma
exacerb
associ
inflammatori
immunolog
cell
infiltr
inflammatori
cell
infiltr
compos
vari
number
eosinophil
neutrophil
lymphocyt
airway
inflamm
combin
smoothmuscl
hypertrophi
step
intermitt
fewer
onceweek
asymptomat
normal
pef
attack
two
fewermonth
less
step
mild
persist
onceweek
fewer
onceday
attack
may
affect
activ
time
month
step
moder
persist
daili
attack
affect
activ
onceweek
step
sever
continu
limit
physic
activ
frequent
less
thicken
lamina
reticulari
accentu
mucu
plug
serum
protein
deposit
inflammatori
cell
cellular
debri
lead
blockag
airway
airflow
obstruct
wheez
approxim
exacerb
associ
respiratori
tract
viral
infect
rhinoviru
respons
twothird
case
asthmat
subject
also
much
sever
lower
respiratori
tract
ill
rhinoviru
infect
healthi
control
subject
mechan
fulli
understood
infect
induc
inflamm
increas
level
neutrophil
eosinophil
cell
cell
mast
cell
increas
mrna
express
translat
eotaxin
protein
chemokin
cc
motif
ligand
proinflammatori
cytokin
virus
implic
exacerb
includ
enteroviru
coronaviru
influenza
parainfluenza
respiratori
syncyti
viru
metapneumoviru
adenoviru
bocaviru
although
influenza
vaccin
recommend
individu
asthma
current
hard
evid
improv
outcom
bacteri
infect
also
implic
asthma
exacerb
individu
asthma
increas
risk
invas
pneumococc
diseas
increas
frequenc
detect
chlamydophila
pneumonia
one
studi
found
mycoplasma
pneumonia
infect
patient
hospit
sever
asthma
sever
trial
evalu
role
macrolid
antibiot
treat
prevent
asthma
exacerb
one
studi
random
adult
exacerb
ketolid
antibiot
telithromycin
placebo
telithromycin
group
small
signific
improv
symptom
lung
function
exacerb
end
treatment
studi
macrolid
antibiot
immunomodulatori
well
antibiot
properti
way
yet
macrolid
antibiot
recommend
intern
asthma
guidelin
new
techniqu
assess
airway
bacteri
microbiota
establish
airway
normal
steril
may
permit
role
bacteri
infect
airway
diseas
delin
recent
studi
found
pathogen
proteobacteria
particularli
haemophilu
speci
much
frequent
bronchi
patient
asthma
copd
control
prolong
exposur
aeroallergen
result
chronic
airway
inflamm
via
ige
mechan
immunolog
reaction
may
intensifi
airway
inflamm
increas
inflammatori
cell
activ
stimul
mucu
gland
hypersecret
lead
airway
obstruct
studi
bronchoalveolar
fluid
allergen
challeng
show
eosinophil
inflamm
major
airway
respons
associ
latephas
respons
airflow
obstruct
addit
significantli
rais
exposur
season
allergen
implic
sudden
asthmarel
death
hdm
cat
cockroach
allergen
sensit
risk
factor
emerg
treatment
grass
pollen
sensit
thunderstorm
asthma
also
associ
epidem
exacerb
fungal
allergen
found
outdoor
indoor
sensit
risk
factor
develop
persist
sever
mortal
associ
asthma
individu
asthma
often
sensit
fungi
cladosporium
speci
alternaria
speci
penicillium
speci
candida
speci
alternaria
speci
sensit
exposur
associ
symptom
increas
risk
respiratori
arrest
subject
asthma
fungal
exposur
may
worsen
diseas
differ
mechan
fungalassoci
proteas
may
lead
develop
allerg
airway
inflamm
along
igemedi
respons
fungal
allergeninduc
asthmat
reaction
evok
respons
increas
eosinophil
recruit
degranul
relationship
fungal
exposur
asthma
complic
degre
sensit
fungal
allergen
result
allergi
specif
diseas
entiti
call
allerg
bronchopulmonari
aspergillosi
abpa
exist
colon
respiratori
tract
ubiquit
aspergillu
fumigatu
associ
increas
allerg
respons
type
type
sever
asthma
exacerb
trial
abpa
relat
diseas
sever
asthma
fungal
sensit
saf
shown
benefit
oral
antifung
itraconazol
goodqual
trial
data
lack
unlik
chronic
condit
gold
standard
diagnosi
asthma
although
test
airway
function
use
diagnos
studi
differ
aspect
airway
diseas
airway
inflammationairway
hyperrespons
diagnosi
still
depend
presenc
specif
symptom
includ
wheez
cough
chest
tight
difficulti
breath
symptom
often
variabl
wors
night
wors
respons
trigger
often
respond
asthma
therapi
may
associ
atopyallergi
famili
histori
similar
problem
lack
gold
standard
affect
clinic
provis
studi
alik
estim
suggest
asthma
wrongli
diagnos
approxim
patient
develop
cheap
reliabl
noninvas
test
diagnos
asthma
seen
holi
grail
diagnosisbas
research
measur
airflow
limit
provid
assess
sever
revers
variabl
airflow
obstruct
help
confirm
diagnosi
asthma
spirometri
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
fev
fvc
prefer
method
measur
airflow
limit
repeat
less
effort
depend
peak
flow
fev
fvc
ratio
less
consist
diagnosi
airflow
obstruct
increas
fev
ml
administr
shortact
bronchodil
indic
revers
airflow
limit
consist
asthma
importantli
asthma
patient
exhibit
revers
assess
repeat
test
advis
confirm
diagnosi
consequ
absent
respons
bronchodil
exclud
asthma
peak
expiratori
flow
pef
measur
use
monitor
asthma
ideal
compar
patient
previou
best
measur
use
peak
flow
meter
improv
lmin
prebronchodil
pef
inhal
bronchodil
diurnal
variat
pef
twicedaili
read
suggest
poorli
control
asthma
approach
util
diagnos
asthma
confirm
formal
diagnosi
identifi
corticosteroid
respons
approach
includ
noninvas
measur
airway
inflamm
assess
airway
hyperrespons
measur
airway
inflamm
rel
easi
either
use
techniqu
induc
sputum
count
differenti
eosinophil
neutrophil
cell
number
present
measur
fraction
nitric
oxid
present
exhal
breath
f
e
use
portabl
chemic
analyz
airway
hyperrespons
assess
sever
differ
method
design
provok
bronchoconstrict
measur
use
spirometri
concentr
dose
bronchoconstrict
occur
use
categor
degre
airway
respons
presenc
absenc
asthma
although
test
wide
employ
research
set
use
clinic
set
hamper
vari
sensit
specif
asthma
diagnosi
airway
inflamm
airway
hyperrespons
present
healthi
individu
without
symptom
symptom
asthma
children
recurr
wheez
cough
difficulti
breath
chest
tight
evalu
symptom
critic
diagnosi
treatment
outcom
measur
use
clinic
studi
howev
asthma
trigger
inflammatori
cell
type
increasingli
use
defin
childhood
asthma
phenotyp
pediatr
asthma
complic
wide
variat
symptom
preval
major
children
asthma
mild
moder
diseas
asthmat
children
chronic
symptom
andor
recurr
exacerb
despit
maximum
treatment
convent
medic
asthma
childhood
heterogen
sever
way
includ
etiolog
clinic
present
respons
treatment
sever
attempt
made
stratifi
treatment
basi
differ
asthma
phenotyp
children
vari
degre
success
stratifi
treatment
pediatr
asthma
complic
patient
age
inabl
depend
age
perform
complic
invas
test
children
onset
progress
asthma
result
complex
interplay
genet
background
environment
exposur
complex
confound
wheez
ill
consist
sever
distinct
diseas
entiti
gener
agreement
number
underli
mechan
among
environment
factor
influenc
risk
asthma
viral
bacteri
respiratori
infect
exposur
environment
tobacco
smoke
also
associ
increas
rate
earli
viral
ill
factor
associ
risk
wheez
includ
physic
factor
associ
increas
breath
exercis
laugh
cri
excit
allergen
aeroallergen
food
allergen
consider
agerel
chang
rel
import
trigger
factor
wheez
children
human
rhinoviru
hrv
implic
etiolog
asthma
exacerb
infant
hrv
infect
wheez
significantli
increas
risk
subsequ
asthma
childhood
asthma
exacerb
trigger
hrv
import
note
exposur
hrv
lead
wheez
ill
children
wheez
ill
result
asthma
case
suggest
host
genotyp
also
play
role
recent
studi
two
cohort
children
asthma
found
variant
locu
associ
asthma
children
hrv
wheez
ill
implic
interact
hrv
wheez
ill
earli
childhood
genotyp
see
section
present
asthma
symptom
exacerb
childhood
also
vari
children
frequent
exacerb
daili
symptom
other
recurr
symptom
without
airway
inflamm
exacerb
diseas
coexist
childhood
asthma
includ
gastroesophag
reflux
diseas
sever
asthma
fungal
sensit
obes
vocal
cord
dysfunct
target
coexist
disord
met
vari
clinic
success
import
compon
develop
asthma
inflammatori
cascad
involv
infiltr
number
inflammatori
cell
eosinophil
neutrophil
band
tlymphocyt
macrophag
mast
cell
dendrit
cell
basophil
airway
releas
inflammatori
mediat
eg
leukotrien
histamin
cytokin
chemokin
airway
structur
cell
includ
epitheli
smoothmuscl
endotheli
fibroblast
cell
howev
sinc
degre
inflamm
asthma
directli
relat
asthma
sever
suggest
factor
structur
chang
airway
also
play
role
diseas
modul
progress
structur
chang
term
airway
remodel
may
exist
presenc
absenc
inflammatori
mechan
airway
inflammatori
respons
asthma
result
excess
activ
mast
cell
airway
earli
respons
allergen
challeng
degranul
mast
cell
result
releas
number
proinflammatori
factor
leukotrien
histamin
caus
immedi
hypersensit
respons
turn
lead
airway
narrow
concomit
releas
inflammatori
factor
cytokin
chemokin
mast
cell
provid
optim
environ
recruit
airway
inflammatori
cell
eosinophil
basophil
neutrophil
tlymphocyt
airway
cell
act
tandem
allergenactiv
macrophag
result
term
late
asthmat
respons
occur
hour
postchalleng
action
number
releas
potent
immunomodul
eg
airway
narrow
occur
may
occur
period
last
hour
inflammatori
cell
involv
asthmat
respons
infiltr
eosinophil
consid
characterist
asthmat
phenotyp
particularli
mildmoder
allerg
asthma
figur
extens
descript
inflammatori
mechan
underli
allerg
asthma
see
hodg
sayer
although
inflamm
asthma
extens
studi
relationship
inflamm
clinic
symptom
asthma
still
unclear
may
partial
explain
possibl
link
airway
inflamm
airway
hyperrespons
airway
becom
suscept
sensit
agent
would
otherwis
unabl
trigger
airway
respons
increas
releas
mediat
histamin
leukotrien
b
abnorm
smoothmuscl
behavior
c
airway
thicken
airway
remodel
play
import
role
asthma
pathogenesi
airway
structur
chang
characterist
airway
remodel
occur
prolong
airway
inflamm
prolong
releas
inflammatori
factor
result
l
thicken
smoothmuscl
bronchial
wall
lead
airway
narrow
l
denud
bronchial
epithelium
l
hyperplasia
hypertrophi
airway
smoothmuscl
l
hyperplasia
hypertrophi
epitheli
goblet
cell
result
format
larg
mucu
plug
liabl
occlud
airway
increas
airway
hyperrespons
airway
remodel
also
involv
chang
occur
extracellular
matrix
constitu
protein
collagen
iiiiiv
fibronectin
laminin
structur
chang
angiogenesi
vasodil
increas
airway
blood
flow
chang
autonom
neurolog
function
develop
asthma
result
degre
airway
remodel
structur
chang
defin
airway
remodel
import
featur
asthmat
airway
even
newli
diagnos
asthma
patient
degre
structur
chang
identifi
bronchial
wall
airway
remodel
defin
process
sustain
disrupt
modif
structur
cell
tissu
lead
develop
new
airway
wall
morpholog
airway
remodel
figur
initi
either
variou
inflammatori
pathway
highlight
import
inflammatori
pathway
bronchial
hyperrespons
airway
remodel
occur
independ
inflamm
understand
extent
natur
genet
variat
human
genom
dramat
improv
sinc
public
first
draft
genom
sequenc
figur
asthma
pathophysiolog
exposur
allergensfor
exampl
dermatophagoid
pteronyssinu
der
dactyli
glomerata
origin
variou
sourc
includ
pollen
hous
dust
mite
mold
taken
dendrit
cell
blymphocyt
epitheli
cell
macrophag
present
antigen
tlympocyt
activ
tlymphocyt
produc
cytokin
regul
immunoglobulin
e
ige
product
blymphocyt
bound
ige
activ
mast
cell
airway
activ
mast
cell
initi
releas
number
factor
includ
leukotrien
histamin
caus
airway
hyperrespons
result
earli
respons
allergen
stimulu
via
bronchoconstrict
concurr
releas
cytokin
chemokin
mast
cell
recruit
eosinophil
basophil
tlymphocyt
airway
cell
associ
cellactiv
neutrophil
antigen
stimul
macrophag
releas
chemokin
leukotrien
extend
period
time
result
late
respons
allergen
stimulu
via
bronchoconstrict
prolong
stimul
laterespons
factor
ultim
lead
airway
structur
chang
mucu
hypersecret
myofibroblast
airway
smoothmuscl
prolifer
common
asthmat
lung
continu
improv
exponenti
initi
genom
project
aim
genomesequ
number
uk
subject
encyclopedia
dna
element
consortium
encod
initi
identifi
genom
regulatori
region
recent
figur
suggest
million
singlenucleotid
polymorph
snp
singlebasepair
chang
exist
genom
consist
billion
base
pair
similarli
grow
realiz
delet
insert
expans
tandem
repeat
also
repres
signific
variat
genet
polymorph
found
throughout
genom
potenti
influenc
gene
function
sever
way
lead
human
diseas
codingregion
nonsynonym
polymorph
alter
amino
acid
sequenc
structurefunct
protein
polymorph
introduc
stop
codon
lead
product
nonfunct
protein
polymorph
regulatori
region
regul
express
level
gene
long
known
atop
diseas
asthma
run
famili
use
atop
proband
nonatop
control
respect
famili
shown
atop
proband
famili
histori
atopi
compar
control
popul
similarli
studi
famili
show
high
concord
asthma
hayfev
eczema
parent
children
twin
studi
use
identifi
signific
concord
asthma
higher
monozygot
twin
ident
genotyp
versu
dizygot
twin
averag
share
half
gene
largest
studi
date
use
danish
twin
pair
suggest
suscept
asthma
genet
substanti
environment
compon
recent
studi
suggest
heredit
estim
asthma
therefor
asthma
consid
complex
genet
disord
contrast
singlegen
disord
eg
cystic
fibrosi
involv
multipl
gene
express
influenc
genet
environment
factor
multipl
environment
factor
import
asthma
develop
includ
tobacco
smoke
exposur
respiratori
viral
infect
antibiot
use
diet
allergen
exposur
gender
ethnic
background
also
make
signific
contribut
complex
mode
inherit
combin
heterogen
present
diseas
made
gene
discoveri
challeng
earli
studi
investig
inherit
famili
contain
multipl
affect
children
use
linkag
analys
candid
gene
approach
base
biolog
locat
genom
howev
figur
asthmat
airway
patholog
schemat
comparison
normal
airway
observ
sever
chronic
asthma
indic
histolog
chang
accompani
recur
inflamm
seen
time
unlik
unaffect
individu
bronchial
mucosa
sever
asthmat
display
thicken
basement
membran
airway
smoothmuscl
hypertrophi
leukocyt
infiltr
epitheli
cell
desquam
goblet
cell
hyperplasia
epitheli
line
accompani
mucu
hypersecret
plug
bronchial
lumen
well
edema
collagen
deposit
submucos
area
drawn
scale
sourc
reproduc
permiss
hodg
sayer
reproduc
find
disappoint
primarili
inadequ
power
subject
heterogen
differ
phenotyp
definit
popul
stratif
multipl
test
without
correct
recent
hypothesisfre
genomewid
associ
studi
gwa
examin
associ
typic
common
frequenc
polymorph
span
genom
case
control
use
stringent
statist
threshold
figur
success
via
multipl
approach
asthma
gene
describ
public
major
reproduc
find
asthma
follow
comprehens
review
see
although
chapter
focus
genet
asthma
diagnosi
subphenotyp
asthma
eg
atopi
serum
total
ige
level
lung
function
eg
fev
also
investig
genet
influenc
posit
clone
involv
linkag
analys
region
whole
genom
follow
fine
map
use
associ
linkag
analysi
use
famili
data
follow
transmiss
genet
inform
span
entir
genom
commonli
short
tandem
repeat
marker
across
gener
data
use
determin
genet
marker
close
link
gene
involv
particular
diseas
use
famili
multipl
affect
children
specif
chromosom
region
identifi
hypothesisfre
approach
snp
span
region
test
see
common
peopl
asthma
compar
peopl
without
first
gene
identifi
confid
use
posit
clone
disintegrin
metalloproteas
use
cohort
famili
linkag
demonstr
locu
chromosom
asthma
bronchial
hyperrespons
bhr
total
ige
level
subsequ
polymorph
span
associ
asthma
second
stage
thought
contribut
airway
remodel
via
enzymat
function
use
posit
clone
multipl
gene
identifi
function
vari
transcript
factor
epitheli
differenti
tissu
remodel
gene
provid
novel
insight
potenti
mechan
alter
asthma
tabl
polymorph
span
urokinas
plasminogen
activ
receptor
plaur
upar
also
associ
asthma
suscept
associ
rate
declin
lung
function
asthma
linkageassoci
analys
chromosom
upar
serin
proteas
receptor
involv
multipl
mechan
includ
cell
prolifer
migrat
extracellular
matrix
degrad
via
plasmin
gener
data
suggest
genet
factor
may
import
determin
airway
structur
chang
remodel
asthma
genotyp
typic
snp
larg
number
case
control
use
array
compar
differ
identifi
diseasespecif
snp
use
stringent
correct
multipl
test
candid
gene
studi
hypothesisdriven
base
suggest
biolog
gene
product
locat
gene
chromosom
region
previous
link
asthma
studi
commonli
employ
asthma
case
versu
control
although
familybas
associ
also
use
excel
review
candid
gene
studi
asthma
see
ober
hoffjan
undarmaa
et
al
primari
highli
reproduc
gene
identifi
use
candid
gene
approach
multipl
compon
interleukin
axi
see
tabl
includ
cytokin
gene
relat
receptor
downstream
signal
effector
signal
transduc
activ
transcript
stat
role
axi
pathogenesi
asthma
extens
document
human
studi
identifi
elev
number
cell
express
mrna
bronchial
tissu
atop
nonatop
asthmat
subject
administr
recombin
mous
lung
result
increas
airway
mucu
secret
develop
subepitheli
fibrosi
airway
hyperrespons
ahr
eosinophil
airway
inflammationthat
sever
key
featur
human
diseas
produc
varieti
cell
includ
cell
mast
cell
basophil
eosinophil
mediat
effect
interact
complex
receptor
system
compris
heterodim
receptor
find
genet
polymorph
within
determin
level
andor
structur
associ
develop
asthma
make
biolog
sens
use
gwa
approach
identifi
asthma
suscept
gene
revolution
understand
asthma
genet
posit
clone
show
great
success
simpl
mendelian
disord
perform
well
complex
diseas
similarli
candid
gene
studi
use
ineffici
capac
interrog
entir
genom
common
snp
case
control
provid
excel
platform
gene
discoveri
first
gwa
asthma
use
discoveri
cohort
patient
childhood
onset
asthma
nonasthma
control
identifi
signific
associ
locu
chromosom
locu
includ
gene
zona
pellucida
bind
protein
gasdermin
b
gsdmb
protein
locu
reproduc
locu
associ
childhood
onset
asthma
mani
studi
howev
identif
specif
gene
underli
effect
remain
resolv
gsdmb
implic
gene
transcript
cell
apoptosi
sphingolipid
synthesi
respect
initi
gwa
supersed
sever
largerscal
studi
particular
gabriel
consortium
studi
involv
asthma
case
control
identifi
associ
polymorph
span
hladq
note
candid
gene
approach
gene
focus
replic
studi
gwa
gene
focus
meet
convent
genomewid
signific
p
andor
independ
replic
caucasian
popul
date
two
reproduc
associ
signal
gene
chromosom
receptor
gene
chromosom
highlight
signific
ligandreceptor
system
asthma
interestingli
loci
associ
sever
asthma
well
good
evid
biolog
axi
may
relev
asthma
mice
induc
develop
allerg
airway
diseas
treat
antibodi
block
bind
receptor
treatment
shown
block
mani
featur
diseas
includ
reduc
serum
ige
airway
eosinophil
lymphocyt
count
significantli
induct
resolut
diseas
attenu
human
studi
shown
elev
airway
asthma
patient
particularli
airway
structur
cell
includ
bronchial
epithelium
induc
cell
relev
stimul
eg
hdm
addit
solubl
form
receptor
shown
elev
asthma
exacerb
overal
thought
axi
may
particularli
import
attract
activ
inflammatori
cell
airway
howev
precis
role
pathway
remain
resolv
outlin
tabl
gene
identifi
use
gwa
includ
involv
divers
role
inflammatori
cell
function
airway
smoothmuscl
contract
provid
uniqu
insight
potenti
alter
mechan
asthma
howev
gwa
determin
singl
variant
confer
modest
odd
ratio
develop
asthma
comprehens
review
gwa
find
asthma
see
akhabir
sandford
last
year
great
progress
identifi
asthma
suscept
gene
current
futur
approach
includ
metaanalys
use
cohort
ten
thousand
asthma
patient
incorpor
gene
expressionsnp
analys
express
quantit
trait
loci
eqtl
investig
asthma
subphenotyp
use
gwa
wholegenom
sequenc
real
challeng
translat
genet
find
deeper
understand
biolog
asthma
potenti
identif
therapeut
target
alreadi
sever
newli
identifi
gene
eg
receptor
repres
excel
pharmacolog
target
anticip
genet
loci
essenti
identifi
patient
like
gain
clinic
benefit
target
pathway
lack
concord
approach
eg
linkag
versu
gwa
explain
fact
methodolog
design
detect
differ
type
variant
eg
linkag
analysi
good
power
detect
highrisk
diseasecaus
allel
effect
identifi
common
allel
modest
effect
gwa
reassur
mani
gene
identifi
candid
gene
approach
reproduc
gwa
eg
locu
chromosom
region
also
link
asthma
much
success
recent
year
identifi
gene
asthma
use
gwa
overal
genet
variat
account
genet
polymorph
small
lead
concept
miss
heredit
possibl
explan
miss
heredit
includ
rare
variant
frequenc
larger
effect
size
measur
exist
platform
structur
variat
eg
copi
number
variat
geneenviron
contribut
genegen
interact
epigenet
mechan
overestim
initi
heredit
aim
treatment
achiev
control
asthma
prevent
exacerb
guidelin
adopt
stepwis
approach
manag
asthma
advis
step
treatment
necessari
step
control
achiev
least
three
month
although
sever
pharmacolog
option
asthma
treatment
see
figur
two
main
class
remain
bronchodil
shortor
longact
corticosteroid
shortact
bronchodil
eg
salbutamolterbutalin
sympathomimet
adrenerg
receptor
agonist
relax
airway
smoothmuscl
enhanc
mucociliari
clearanc
decreas
vascular
permeabl
possibl
modul
mediat
releas
mast
cell
use
symptom
control
acut
exacerb
exerciseinduc
asthma
frequent
regularli
schedul
use
rapidact
inhal
agonist
longterm
manag
asthma
adequ
control
symptom
pef
variabl
airway
inflamm
longact
bronchodil
eg
salmeterolformoterol
activ
ident
shortact
adrenerg
receptor
agonist
use
combin
inhal
corticosteroid
concern
regard
increas
mortal
use
monotherapi
longact
bronchodil
normal
introduc
treatment
step
inhal
corticosteroid
ic
form
backbon
treatment
mildest
asthma
ic
improv
lung
function
symptom
qualiti
life
reduc
exacerb
improv
mortal
broad
antiinflammatori
immunosuppress
effect
corticosteroid
enter
cell
cytoplasm
bind
inact
glucocorticoid
receptor
complex
activ
glucocorticoid
receptor
bind
dna
glucocorticoid
respons
element
sequenc
promot
synthesi
antiinflammatori
protein
transactiv
inhibit
transcript
synthesi
mani
proinflammatori
cytokin
transrepress
also
reduc
number
tlymphocyt
dendrit
cell
eosinophil
mast
cell
airway
reduc
induc
nitric
oxid
product
ic
beclomethason
dipropionatefluticason
propionatebudesonid
flunisolideciclesonidemometason
side
effect
relat
transactiv
properti
includ
local
effect
oropharynx
hoars
candidiasi
cough
dysphonia
system
effect
cush
syndrom
osteoporosi
cataract
dermal
thin
bruis
adren
insuffici
growth
suppress
children
consequ
lowest
dose
requir
control
symptom
prevent
exacerb
prescrib
medic
normal
reserv
secondor
thirdlin
treatment
includ
methylxanthin
theophyllin
leukotrien
modifi
montelukast
inhal
anticholinerg
ipratropium
bromidetiotropium
sodium
chromoglyc
wide
rang
intervent
assess
primari
prevent
asthma
secondari
prophylaxi
diseas
present
treatment
vari
effect
may
recommend
individu
case
primari
prevent
measur
includ
aeroallergen
food
allergen
avoid
fish
oil
supplement
avoid
tobacco
smoke
air
pollut
immunotherapi
immun
measur
assess
secondari
prophylaxi
includ
hdm
allergen
avoid
smoke
reduct
subcutan
sublingu
immunotherapi
dietari
manipul
weight
loss
breath
techniqu
exercis
train
investig
argu
sever
asthma
inflammatori
condit
separ
mildmoder
asthma
rather
simpli
sever
end
diseas
spectrum
difficult
prove
underli
asthma
may
complic
aspect
obesityrefluxsmokingpoor
adher
make
difficult
treat
control
differ
definit
sever
asthma
requir
highdos
inhal
corticosteroid
oral
corticosteroid
includ
recurr
exacerb
poor
control
highdos
ic
oral
corticosteroid
associ
side
effect
attempt
made
design
treatment
either
reduc
amount
corticosteroid
prescrib
steroidspar
agent
treat
underli
asthma
differ
manner
steroidspar
agent
triall
includ
methotrex
gold
cyclosporin
azathioprin
current
none
recommend
asthma
guidelin
box
list
treatment
use
individu
basi
need
stratifiedmedicin
approach
asthma
becom
appar
last
decad
follow
realiz
term
asthma
cover
whole
rang
diseas
phenotyp
techniqu
investig
research
asthma
evolv
becom
clear
differ
diseas
process
present
requir
differ
treatment
approach
whether
repres
diseas
phenotyp
better
understand
diseas
pathogenesi
unclear
year
research
focu
move
airway
smoothmuscl
via
airway
inflamm
airway
immunolog
epithelialmesenchym
trophic
unit
futur
insight
diseas
pathogenesi
new
treatment
develop
follow
use
latest
technolog
includ
omic
platform
assess
airway
microbiota
improv
understand
stratifi
medicin
asthmatarget
right
therapi
right
patientaim
reduc
hospit
admiss
due
poorli
control
asthma
fatal
although
asthma
control
ic
bronchodil
remain
cohort
patient
persist
symptom
recurr
exacerb
wors
qualiti
life
current
stepwis
manag
approach
see
figur
ineffici
particularli
light
heterogen
clinic
present
respons
exist
therapi
make
stratifi
approach
essenti
earli
work
conceptu
asthma
extrins
allerg
intrins
nonallerg
howev
recent
use
unbias
approach
classifi
diseas
use
three
larg
dataset
cluster
analysi
highlight
differ
type
diseas
umbrella
term
asthma
figur
although
earli
studi
perform
differ
part
world
statist
variat
result
similar
age
diseas
onset
found
key
differenti
factor
earlyonset
diseas
associ
atop
allerg
condit
wherea
lateronset
diseas
associ
eosinophil
inflamm
obes
studi
limit
crosssect
design
fact
treatment
may
determin
cluster
longitudin
studi
initi
childhood
ongo
exampl
pacman
formal
pharmacogenet
asthma
medic
children
medic
antiinflammatori
effect
aim
differenti
children
uncontrol
asthma
despit
ic
treatment
use
rang
clinic
cellular
marker
role
allergi
inappropri
harm
immun
respons
normal
nonharm
substanc
requir
sensit
atopi
tendenc
develop
ige
antibodi
commonli
encount
environment
allergen
natur
exposur
rout
entri
across
intact
mucos
surfac
well
studi
asthma
peopl
extrins
asthma
thought
develop
diseas
earlier
life
atop
identifi
allerg
trigger
well
allerg
diseas
rhiniti
eczema
intrins
asthma
thought
develop
later
life
year
age
associ
aspirinexacerb
respiratori
diseas
allerg
sensit
small
studi
human
suggest
level
cytokin
similar
extrins
antiig
bronchial
thermoplasti
macrolid
antibiot
antifung
itraconazolevoriconazol
box
new
emerg
therapi
reserv
sever
asthma
intrins
asthma
treatment
ic
effect
major
mild
moder
asthma
case
distinct
extrins
intrins
asthma
fell
favor
heterogen
respons
exist
medic
exemplifi
malmstrom
studi
investig
individu
respons
leukotrien
receptor
antagonist
ltra
montelukast
mg
daili
inhal
steroid
beclomethason
twice
daili
period
chronic
asthma
patient
overal
clear
improv
lung
function
primari
outcom
fev
treatment
howev
stratifi
base
individu
patient
data
larg
degre
heterogen
treatment
group
patient
show
improv
fev
other
show
declin
lung
function
decreas
fev
figur
interindividu
variabl
compon
clinic
trial
seldom
appreci
thought
strong
genet
compon
therapeut
regimen
treatment
asthma
well
defin
describ
earlier
chapter
despit
welldefin
treatment
regimen
constantli
updat
streamlin
well
avail
highqual
medic
mani
case
asthma
still
suffici
control
current
asthma
therapeut
abl
success
treat
asthmat
popul
around
still
daili
symptom
almost
patient
report
limit
daili
activ
also
leav
around
patient
respond
convent
treatment
demonstr
current
onesizefitsal
approach
perfect
emphas
need
stratifi
medicin
approach
asthma
variabl
current
therapi
involv
variat
drug
efficaci
present
side
effect
present
challeng
success
mainten
asthma
variabl
drug
efficaci
especi
occur
adrenerg
receptor
agonist
glucocorticosteroid
present
side
effect
result
patient
therapi
deviat
standard
therapeut
regimen
treatment
asthma
high
degre
interpati
variabl
treatment
respons
side
effect
attribut
number
factor
interact
genet
factor
individu
patient
characterist
weight
gender
pregnanc
exposur
environment
insult
air
pollut
allergen
cigarett
smoke
factor
interact
make
control
asthmat
episod
reduct
exacerb
difficult
exampl
asthma
attack
affect
differ
age
group
differ
accord
seasonchildren
affect
summer
older
popul
suffer
winter
consid
variat
treatment
efficaci
one
must
also
mind
individu
patient
factor
inhal
techniqu
noncompli
discuss
earlier
current
asthma
therapi
plan
without
consider
genet
varianc
howev
genet
varianc
arguabl
import
factor
list
previouslya
claim
support
evid
gain
investig
repeat
respons
therapi
approach
demonstr
repeat
substanti
proport
varianc
due
genet
factor
one
import
form
varianc
therapeut
efficaci
nonrespons
nonrespons
import
limit
mainten
control
asthma
therapeut
expect
manag
diseas
certain
level
sever
fail
outright
lead
use
trial
approach
differ
therapi
util
variabl
result
suitabl
regimen
determin
good
exampl
sever
asthma
patient
perman
oral
glucocorticosteroid
therapi
nonrespons
therapi
ic
leukotrien
receptor
antagonist
adrenerg
receptor
agonist
nonrespond
present
longer
durat
asthma
exacerb
wors
morn
lung
function
well
frequent
famili
histori
asthma
compar
individu
respons
glucocorticosteroid
therapi
recognit
allergen
specif
ige
activ
mast
cell
central
drive
allerg
asthma
lead
discoveri
primari
mast
cellsign
cascad
could
inhibit
monoclon
antibodi
toward
ige
bind
site
high
affin
receptor
antiig
omalizumab
becam
first
specif
biolog
use
treatment
sever
allerg
asthma
clinic
trial
reveal
efficaci
well
almost
total
inhibit
earli
late
asthmat
respons
inhal
allergen
follow
rigor
examin
trial
data
nation
institut
clinic
excel
nice
omalizumab
recommend
option
treat
sever
individu
data
persist
confirm
allerg
igemedi
asthma
addon
optim
standard
therapi
peopl
age
six
older
need
continu
frequent
treatment
oral
corticosteroid
defin
four
cours
previou
year
unit
kingdom
although
drug
prescrib
case
therapyresist
asthma
associ
allergi
also
licens
patient
evid
allergi
normal
ige
omalizumab
repres
first
stratifi
treatment
asthma
evid
use
stratifi
use
biomark
inflamm
predict
respons
recent
paper
studi
effect
omalizumab
uncontrol
sever
persist
allerg
asthma
treatment
effect
analyz
relat
f
e
blood
eosinophil
serum
periostin
epitheli
protein
induc
week
omalizumab
reduct
protocoldefin
exacerb
greater
high
versu
low
subgroup
three
biomark
suggest
potenti
prognost
abil
biomark
approach
help
divid
asthma
high
low
diseas
asthma
tradit
consid
process
link
atopi
allergi
type
hypersensit
reaction
eosinophil
inflamm
respons
corticosteroid
high
diseas
evidenc
high
f
e
sputum
eosinophilia
associ
better
respons
corticosteroid
compar
low
diseas
studi
lebrikizumab
novel
monoclon
antibodi
suggest
serum
periostin
may
biomark
gener
asthmat
phenotyp
one
studi
subgroup
individu
asthma
persist
elev
serum
periostin
show
greater
improv
airway
function
fewer
exacerb
lebrikizumab
treatment
lower
serum
periostin
interestingli
level
f
e
produc
induc
nitric
oxid
synthas
enzym
induc
human
airway
epitheli
cell
inform
periostin
identifi
individu
respons
lebrikizumab
role
stratif
base
phenotyp
need
correct
studi
end
point
treatment
trial
inform
salutari
lesson
antibodi
mepolizumab
although
mepoluzimab
effect
block
eosinophil
inflamm
initi
studi
disappoint
effect
demonstr
spirometri
peak
flow
despit
signific
reduct
blood
eosinophil
number
effect
drug
studi
outcom
measur
relat
eosinophilia
name
sever
exacerb
significantli
fewer
exacerb
concomit
improv
asthmarel
qualiti
life
tellingli
signific
differ
respect
symptom
postbronchodil
fev
airway
hyperrespons
suggest
differ
physiolog
process
determin
asthma
outcom
studi
also
help
research
reflect
upon
need
measur
correct
end
point
diseas
differ
patholog
mechan
respond
differ
treatment
phenotyp
asthma
led
identif
new
diseas
target
asid
use
antiig
yet
led
step
chang
manag
approach
assess
separ
aspect
asthma
pathophysiologynam
airway
inflamm
airway
hyperrespons
airflow
obstruct
triall
differ
result
key
determin
design
stratifi
approach
recognit
although
asthma
diseas
defin
symptom
treatment
respons
also
assess
symptom
improv
clear
correl
pathophysiolog
symptomatolog
exacerb
risk
facet
studi
design
evalu
benefit
ad
longact
adrenerg
receptor
agonist
differ
dose
ic
higherdos
ic
mark
benefici
effect
exacerb
frequenc
rel
less
effect
symptom
peak
expiratori
flow
opposit
true
addit
longact
agonist
indic
exacerb
frequenc
close
relat
symptom
measur
disord
airway
function
suggest
mechan
respons
featur
differ
numer
studi
demonstr
asthma
featur
airway
inflamm
airway
hyperrespons
variabl
airflow
obstruct
associ
symptom
overlap
occur
independ
chang
time
respons
treatment
extern
factor
allergen
exposur
viral
infect
one
obviou
exampl
eosinophil
bronchiti
condit
character
corticosteroidrespons
cough
presenc
sputum
eosinophilia
occur
absenc
variabl
airflow
obstruct
airway
hyperrespons
although
asthma
guidelin
recommend
assess
airflow
obstruct
fev
pef
relat
symptom
primari
treatment
respons
outcom
realiz
approach
look
one
aspect
asthma
pathophysiolog
close
relat
exacerb
risk
led
new
approach
aim
reduc
asthma
exacerb
symptom
maintain
corticosteroid
burden
lowest
possibl
level
airway
hyperrespons
defin
increas
sensit
inhal
constrictor
agonist
steeper
slope
doserespons
curv
two
main
form
bronchoconstrictor
stimuli
exist
direct
indirect
direct
bronchoconstrictor
histamin
methacholin
stimul
receptor
airway
smoothmuscl
indirect
one
caus
bronchoconstrict
secondari
releas
bronchoconstrictor
mediat
mast
cell
activ
neural
pathway
airway
respons
usual
measur
provoc
dose
methacholin
caus
fall
fev
linear
interpol
log
doserespons
curv
pc
gener
popul
distribut
airway
hyperrespons
follow
continu
unimod
lognorm
distribut
asthma
suffer
repres
hyperrespons
part
distribut
curv
pc
usual
measur
nondiseas
individu
suggest
larg
differ
airway
respons
nondiseas
individu
asthma
patient
cutoff
use
identifi
asthma
normal
methacholin
concentr
mgml
valu
sensit
specif
neg
predict
valu
studi
popul
colleg
student
diagnosi
current
symptomat
asthma
use
methacholin
pc
diagnos
asthma
evalu
one
studi
demonstr
asthma
defin
consist
symptom
object
evid
abnorm
variabl
airflow
obstruct
posit
methacholin
challeng
sensit
pef
amplitud
mean
acut
bronchodil
respons
diagnosi
use
methacholin
pc
guid
treatment
also
assess
although
found
pc
guid
treatment
result
reduct
asthma
exacerb
expens
increas
inhal
corticosteroid
use
consequ
although
pc
often
use
asthma
diagnosi
studi
end
point
routin
use
guid
treatment
decis
asthma
tradit
view
condit
airway
inflamm
caus
airway
hyperrespons
turn
lead
variabl
airflow
obstruct
symptom
howev
crosssect
longitudin
studi
airway
inflamm
use
sputum
induct
larg
popul
divers
rang
present
suggest
hypothesi
requir
modif
recent
bronchoscopi
studi
demonstr
bronchoconstrict
independ
airway
inflamm
lead
airway
remodel
develop
noninvas
techniqu
assess
airway
inflamm
includ
induc
sputum
f
e
made
possibl
relat
airway
inflamm
object
measur
disord
airway
function
larger
heterogen
popul
possibl
bronchoscopi
studi
gener
newer
studi
contradict
find
earlier
studi
find
correl
sputum
eosinophil
count
variou
marker
airway
dysfunct
observ
subset
patient
symptomat
asthma
sputum
evid
eosinophil
airway
inflamm
mani
sputum
neutrophilia
sputum
profil
evid
well
corticosteroidtr
subject
suggest
alway
artifact
relat
treatment
importantli
patient
noneosinophil
asthma
respond
less
well
inhal
budesonid
group
typic
sputum
featur
similar
sputum
find
report
sever
asthmat
subgroup
patient
refractori
asthma
identifi
bronchoscop
evid
neutrophil
airway
inflamm
normal
eosinophil
count
normal
basement
membran
thick
find
suggest
presenc
distinct
asthma
phenotyp
character
predominantli
neutrophil
airway
inflammatori
respons
rel
corticosteroid
resist
furthermor
evid
neutrophil
asthma
may
result
activ
innat
immun
system
product
proinflammatori
cytokin
use
noninvas
measur
guid
treatment
decis
stratif
base
presenc
absenc
airway
inflamm
assess
strongest
evid
effect
relat
use
induc
sputum
guid
corticosteroid
dose
moder
sever
asthma
two
studi
shown
use
induc
sputum
differenti
count
guid
treatment
result
fewer
exacerb
overal
corticosteroid
burden
although
evid
clear
approach
work
induc
sputum
wide
employ
possibl
seen
time
consum
requir
expertis
induc
sputum
perform
differenti
count
discoveri
level
f
e
measur
via
devic
similar
breathalyz
correl
well
sputum
eosinophilia
relat
corticosteroid
respons
driven
applic
inflammometri
noninvas
measur
inflamm
airway
inflammometri
use
f
e
measur
also
use
guid
stratifi
treatment
decis
though
one
studi
posit
patient
asthma
pregnanc
reduct
exacerb
fail
show
improv
compar
guidelinedriven
fev
pef
symptom
manag
hunt
still
reliabl
inexpens
valid
biomark
airway
inflamm
fev
pef
measur
reflect
chang
calib
larg
airway
knowledg
anatom
physiolog
chang
small
airway
patient
asthma
base
small
case
seri
resect
lung
tissu
patient
asthma
undergo
surgeri
cancer
case
fatal
asthma
case
seri
demonstr
signific
inflamm
present
small
airway
mm
diamet
asthma
fatal
asthma
associ
peripher
airway
inflamm
differ
number
activ
eosinophil
distal
lung
studi
reveal
alter
epithelium
smoothmuscl
well
mucou
hypersecret
distal
airway
plug
small
airway
presenc
inflamm
small
airway
asthma
may
explain
small
airway
account
total
airflow
resist
asthma
airflow
resist
normal
airway
recent
develop
smallparticl
ic
design
target
peripher
lung
advent
new
technologiesnitrogen
washout
impuls
oscillometri
hyperpolar
nobl
ga
magnet
reson
imag
allow
assess
peripher
lung
functionhav
led
resurg
interest
distal
lung
studi
smallparticl
ic
inconsist
compar
smallparticl
standardparticl
icss
fail
demonstr
improv
asthma
outcom
administ
clinic
compar
dose
futur
asthma
treatment
may
yet
stratifi
presenc
absenc
small
airway
inflamm
sever
attempt
base
treatment
decis
measur
airway
inflamm
includ
induc
sputum
f
e
children
gener
unsuccess
although
expert
stratifi
treatment
decis
respons
oral
intramuscular
steroid
method
stratifi
asthma
patient
specif
treatment
base
nongenet
factor
clinic
outcom
cellular
measur
protein
biomark
shown
success
larg
bodi
work
investig
potenti
genet
marker
predictor
patient
respons
exist
therapi
ie
pharmacogenet
pharmacogenet
investig
effect
genet
polymorph
respons
treatment
risk
advers
side
effect
one
first
step
develop
person
prescrib
use
genet
inform
stratifi
patient
prescrib
potenti
desir
compar
nongenet
stratif
technolog
allow
small
amount
blood
saliva
sampl
taken
dna
test
complet
within
hour
date
asthma
pharmacogenet
studi
suffer
rel
small
retrospect
design
focu
candid
gene
howev
recent
larger
prospect
studi
complet
provid
greater
confid
origin
find
hypothesisfre
approach
gwa
studi
primarili
focus
pharmacodynam
aspect
eg
improv
lung
function
posttreat
limit
inform
avail
impact
pharmacogenet
advers
effect
pharmacogenet
asthma
rel
advanc
compar
diseas
genet
factor
influenc
main
treatment
class
ie
adrenerg
receptor
agonist
corticosteroid
leukotrien
modifi
identifi
confid
tabl
overview
find
follow
howev
indepth
analys
see
portelli
sayer
adrenerg
receptor
agonist
carri
function
adrenerg
receptora
gproteincoupl
receptor
encod
intronless
gene
locat
chromosom
bind
agonist
receptor
activ
adenyl
cyclas
stimulatori
gs
protein
turn
activ
protein
kinas
latter
phosphoryl
sever
target
protein
result
decreas
intracellular
calcium
importantli
caus
smoothmuscl
relax
airway
surpris
major
evid
genet
driven
effect
adrenerg
receptoragonist
therapi
stem
gene
therefor
extens
studi
pharmacogenet
effect
adrenerg
receptoragonist
respons
highli
polymorph
gene
contain
known
valid
polymorph
snp
insertiondelet
variant
studi
focus
role
four
nonsynonym
codingregion
polymorph
argininetoglycin
substitut
posit
protein
caucasian
popul
frequenc
polymorph
posit
identifi
remain
polymorph
rare
approxim
frequenc
respect
variant
shown
pharmacogenet
potenti
associ
enhanc
acut
respons
adrenerg
receptor
agonist
l
declin
asthma
control
follow
prolong
use
adrenerg
receptor
agonist
l
subsensit
respons
bronchoprotect
adrenerg
receptor
agonist
howev
sever
studi
fail
reproduc
effect
mean
common
consensu
contribut
yet
reach
lack
consensu
explain
consid
least
differ
haplotyp
specif
combin
snp
across
gene
investig
effect
genotyp
isol
without
consider
haplotyp
like
introduc
confound
associ
function
effect
codingregion
polymorph
identifi
vitro
work
carri
cell
line
includ
follow
one
larger
studi
basu
et
al
identifi
copi
numberdepend
increas
diseas
exacerb
patient
asthma
age
year
daili
exposur
adrenerg
receptor
agonist
regularli
inhal
corticosteroid
plu
salbutamol
demand
group
regularli
inhal
corticosteroid
plu
salmeterol
salbutamol
demand
group
import
note
effect
driven
asthma
patient
use
salbutamol
andor
salmeterol
daili
support
suggest
polymorph
integr
role
effect
adrenerg
receptoragonist
therapi
howev
studi
studi
limit
allow
clear
associ
made
gene
via
polymorph
adrenerg
receptoragonist
efficaci
name
particip
use
adrenerg
receptoragonist
reliev
studi
arm
adrenerg
receptoragonist
reliev
use
would
provid
clearer
interpret
detriment
effect
salbutamolsalmeterol
subject
larg
studi
fail
observ
clinic
relev
effect
polymorph
includ
longitudin
studi
adrenerg
receptoragonist
efficaci
studi
concomit
administr
corticosteroid
good
exampl
studi
asthma
patient
randomli
assign
budesonid
plu
formoterol
mainten
reliev
therapi
fixeddos
budesonid
plu
formoterol
fix
dose
fluticason
plu
salmeterol
six
month
overal
effect
genotyp
clinic
outcom
found
anoth
contribut
factor
pronounc
differ
conclus
differ
studi
investig
polymorph
trial
design
variat
major
studi
focus
polymorph
howev
potenti
pharmacogenet
relev
polymorph
also
affect
adrenerg
receptoragonist
efficaci
multipl
polymorph
gene
regulatori
region
potenti
clinic
relev
present
studi
eight
common
haplotyp
base
snp
recent
vitro
approach
use
whole
gene
transfect
identifi
differenti
effect
receptor
express
downregul
haplotypedriven
studi
identifi
four
common
haplotyp
elev
receptor
express
two
haplotyp
enhanc
receptor
downregul
anoth
area
recent
investig
polymorph
occur
gene
untransl
region
may
effect
gene
express
result
drug
efficaci
multipl
gene
like
involv
regul
adrenerg
receptoragonist
respons
express
side
effect
due
agonist
known
complex
multifactori
mechan
action
one
gene
associ
patient
respons
agonist
arginas
identifi
use
novel
algorithm
implement
familybas
associ
test
fbat
studi
children
parent
snp
associ
bronchodil
respons
bdr
snp
candid
gene
involv
adrenerg
receptorsignalingregul
involv
glucocorticoid
regul
prior
asthma
associ
studi
investig
associ
acut
respons
inhal
adrenerg
receptoragonist
children
parent
agreement
studi
polymorph
span
influenc
patient
respons
salbutamol
also
identifi
candid
gene
studi
involv
asthma
subject
polymorph
identifi
studi
linkag
disequilibrium
ld
inherit
togeth
suggest
common
caus
mechan
involv
potenti
transcript
regul
due
polymorph
locat
predominantli
gene
alter
transcript
confirm
promoterreport
studi
found
key
haplotyp
associ
improv
bdr
drive
highest
level
promot
activ
studi
vonk
et
al
snp
also
associ
patient
respons
salbutamol
suggest
integr
role
arginas
famili
adrenerg
receptoragonist
therapi
recent
snitrosoglutathion
reductas
gsnor
snp
promot
region
associ
decreas
respons
salbutamol
africanamerican
children
studi
post
hoc
multilocu
analysi
discov
combin
carbamoyl
phosphat
snp
gave
predict
valu
lack
respons
therapi
impli
pharmacogenet
regul
adrenerg
receptoragonist
therapi
may
depend
sever
loci
act
togeth
via
genegen
interact
confirm
snp
test
gsnor
associ
asthma
patient
respons
salbutamol
puerto
rican
asthma
patient
snp
also
associ
asthma
suscept
key
risk
haplotyp
associ
increas
transcript
activ
base
promoterreport
studi
gsnor
alcohol
dehydrogenas
break
gsno
endogen
bronchodil
addit
gsno
regul
nitrosyl
protein
lead
alter
function
includ
gprotein
coupl
receptor
kinas
phosphoryl
desensit
adrenerg
receptor
novel
gene
recent
associ
adrenerg
receptoragonist
therapi
includ
spermatogenesisassoci
serinerich
collagen
gene
gene
associ
intron
snp
associ
acut
bronchodil
respons
inhal
salbutamol
genomewid
associ
studi
snp
test
caucasian
trio
associ
replic
pool
popul
three
asthma
trial
popul
well
three
addit
asthma
popul
also
identifi
modul
adrenerg
receptoragonist
function
gwa
snp
locat
near
gene
significantli
associ
percentag
chang
baselin
fev
caucasian
asthma
patient
replic
two
altern
caucasian
popul
n
molecular
biolog
techniqu
confirm
result
identifi
may
import
regul
adrenerg
receptor
downregul
identif
patient
risk
potenti
advers
effect
adrenerg
receptoragonist
remain
critic
clinic
question
target
class
drug
patient
like
benefit
clear
progress
respect
studi
design
eg
examin
haplotyp
instead
genotyp
isol
adequ
power
studi
use
thousand
individu
still
need
larg
prospect
studi
asthma
patient
match
phenotyp
care
control
covari
includ
environment
influenc
similarli
studi
would
benefit
gwa
approach
identif
genegen
interact
investig
effect
genet
polymorph
adrenerg
receptoragonist
respons
predominantli
focus
clinic
end
point
eg
lung
function
paramet
differ
genotyp
group
recent
interest
reallif
applic
genet
knowledg
outlin
firstlin
treatment
asthma
shortact
adrenerg
receptoragonist
eg
salbutamol
need
step
symptom
persist
addit
inhal
corticosteroid
eg
beclomethason
consid
step
control
longact
adrenerg
receptor
agonist
eg
salmeterol
leukotrien
receptor
antagonist
ltra
eg
montelukast
ad
step
figur
recent
studi
lipworth
et
al
set
use
genet
inform
polymorph
inform
choic
prescrib
salmeterol
montelukast
addon
therapi
children
persist
asthma
homozyg
genotyp
n
random
receiv
salmeterol
bd
montelukast
mg
daili
addon
inhal
fluticason
propion
one
year
studi
test
whether
carrier
genotyp
prone
advers
effect
eg
prolong
adrenerg
receptoragonist
use
associ
exacerb
henc
whether
montelukast
provid
superior
control
preselect
popul
outcom
school
absenc
primari
outcom
exacerb
score
reliev
use
salbutamol
morn
dyspnoea
asthma
control
questionnair
acq
qualityoflif
score
montelukast
provid
superior
benefit
measur
clinic
relev
differ
within
three
month
signific
differ
fev
pred
observ
provid
evid
limit
correl
lung
function
symptombas
score
result
suggest
larger
longer
prospect
studi
warrant
provid
definit
data
clinic
util
stratif
includ
studi
arm
use
addit
marker
defin
popul
would
provid
clearer
interpret
outlin
leukotrien
synthesi
inhibitor
ltsi
leukotrien
receptor
antagonist
ltra
commonli
use
addon
therapi
asthma
provid
greater
control
steroidspar
effect
cysteinyl
leukotrien
ltc
ltd
lte
dihydroxi
leukotrien
ltb
contribut
inflammatori
process
asthma
synthes
arachidon
acid
via
pathway
figur
cysteinyl
leukotrien
implic
bronchoconstrict
mucu
secret
vascular
permeabl
inflammatori
cell
infiltr
cytokin
product
arachidon
acid
convert
acid
leukotrien
lta
protein
act
adaptor
protein
reaction
lta
convert
leukotrien
b
ltb
lta
hydrolas
altern
conjug
reduc
glutathion
form
ltc
via
action
leukotrien
ltc
synthas
ltc
next
transport
extracellular
space
via
multidrug
resist
protein
figur
leukotrien
modifi
includ
ltsi
act
target
eg
zileuton
result
decreas
leukotrien
biosynthesi
ltc
ltd
lte
ltb
ltra
act
specif
block
cysteinyl
leukotrien
bind
primari
receptor
found
mani
cell
type
includ
inflammatori
cell
airway
smoothmuscl
cell
eg
montelukast
zafirlukast
data
demonstr
larg
degre
heterogen
asthma
patient
respons
class
drug
summar
figur
data
led
extens
genet
studi
investig
role
snp
larg
number
candid
gene
associ
leukotrien
product
andor
activ
acut
respons
ltra
ltsi
associ
describ
polymorph
howev
mani
studi
small
led
lack
reproduc
find
recent
studi
look
differ
aspect
leukotrien
modifi
function
includ
associ
montelukast
absorpt
ie
pharmacokinet
polymorph
howev
other
fail
observ
associ
along
protein
major
regulatori
switch
leukotrien
product
extens
studi
demonstr
level
dramat
effect
cysteinyl
dihydroxi
leukotrien
product
catalyz
convers
arachidon
acid
lta
one
earli
stage
leukotrien
product
figur
found
chromosom
larg
gene
compos
exon
intron
span
approxim
kb
multipl
studi
suggest
polymorph
influenc
clinic
respons
ltra
ltsisin
particular
function
repeat
polymorph
promot
region
result
alter
transcript
factor
bind
associ
alter
gene
transcript
respons
ltsi
earli
studi
extend
investig
multipl
polymorph
span
entir
gene
associ
ltra
andor
ltsi
respons
asthma
patient
exampl
tantisira
et
al
observ
associ
intron
chang
fev
postltsi
zileuton
cohort
asthma
patient
snp
also
predictor
respons
ltra
montelukast
previou
studi
asthma
subject
use
percentag
chang
fev
primari
outcom
case
gg
versu
ga
aa
genotyp
greatest
improv
lung
function
fev
postdrug
lack
associ
snp
montelukast
studi
may
due
reduc
power
studi
compar
zileuton
studi
function
signific
snp
remain
resolv
import
note
may
caus
genet
chang
polymorph
inherit
time
ie
ld
may
relev
two
snp
synonym
region
also
associ
improv
pef
treatment
montelukast
studi
asthma
patient
confirm
relev
snp
key
enzym
leukotrien
product
addit
support
relev
asthma
control
provid
recent
studi
children
found
promot
polymorph
determin
urinari
lte
level
associ
reduc
lung
function
potenti
acq
score
copi
carrier
studi
invers
relationship
urinari
lte
level
fev
anoth
import
enzym
leukotrien
pathway
leukotrien
c
synthas
specif
result
gener
first
cysteinyl
leukotrien
ltc
conjug
glutathion
lta
intens
research
role
asthma
suscept
enzym
like
thought
key
regulatori
switch
cysteinyl
leukotrien
thought
play
promin
role
asthma
eg
via
bronchoconstrict
dihydroxi
ltb
rel
small
span
kb
chromosom
particular
promot
polymorph
intens
investig
pharmacogenet
effect
thought
alter
level
via
transcript
higher
level
c
allel
carrier
therefor
alter
ltc
product
ten
publish
studi
investig
role
c
five
show
improv
outcom
measur
includ
fev
postltra
therapi
carrier
c
allel
hypothes
although
result
alway
statist
signific
recent
studi
zileuton
respons
fev
chang
time
asthma
subject
polymorph
show
effect
howev
altern
polymorph
intron
associ
improv
respons
mean
fev
result
obtain
differ
popul
use
differ
end
point
rel
contribut
polymorph
ltra
ltsi
therapeut
respons
asthma
still
unclear
larger
prospect
studi
use
multipl
ethnic
group
requir
montelukast
ltra
target
cysteinyl
leukotrien
receptor
express
varieti
cell
includ
airway
smoothmuscl
variou
inflammatori
cell
eg
eosinophil
therefor
inhibit
activ
receptor
cysteinyl
leukotrien
figur
cysteinyl
leukotrien
receptor
thought
main
receptor
mediat
cysteinyl
leukotrien
receptor
smoothmuscl
contract
inflammatori
cell
cytokin
product
asthma
genet
variat
target
receptor
compound
may
influenc
effect
carrier
allel
regul
receptor
functionexpress
cysteinyl
leukotrien
receptor
gene
intronless
found
chromosom
gener
amino
acid
gproteincoupl
receptor
gpcr
second
receptor
cysteinyl
leukotrien
also
describ
target
ltra
may
modul
effect
cysteinyl
leukotrien
vivo
gene
cysteinyl
leukotrien
receptor
found
chromosom
encod
amino
acid
gpcr
interestingli
combin
sever
snp
polymorph
span
identifi
determin
respons
montelukast
suggest
snpsnp
interact
may
import
howev
direct
evalu
polymorph
respons
montelukast
zileuton
identifi
signific
effect
date
studi
limit
howev
snp
associ
improv
morn
pef
follow
administr
montelukast
week
major
studi
focus
candid
polymorph
analys
gene
directli
involv
leukotrien
product
activ
sever
studi
identifi
addit
gene
relev
ltsi
ltra
respons
addit
effect
vasodil
bronchoconstrict
prostaglandin
receptor
gene
ptgdr
thought
regul
least
part
level
leukotrien
c
studi
asthmat
children
prescrib
montelukast
mgday
modest
effect
observ
similarli
extens
studi
snp
candid
gene
asthma
patient
prescrib
fluticason
fluticason
propion
plu
salmeterol
montelukast
signific
associ
four
snp
cholinerg
muscarin
receptor
gene
montelukast
respons
chang
fev
week
observ
thought
mediat
airway
tone
via
regul
contractilerelax
respons
target
use
antagonist
exampl
tiotropium
shown
clinic
efficaci
multipl
respiratori
diseas
data
potenti
suggest
natur
airway
obstructionton
determin
alter
express
andor
activ
may
influenc
respons
montelukast
major
studi
investig
associ
gene
polymorph
acut
respons
asthma
therapi
recent
studi
mougey
et
al
identifi
solut
carrier
organ
anion
transport
famili
member
altern
name
organ
anion
transport
abl
mediat
montelukast
permeabl
use
model
cell
system
engin
express
protein
subsequ
group
also
show
alter
protein
structur
occur
naturallythat
associ
reduc
morn
plasma
concentr
montelukast
follow
even
dose
one
month
six
month
treatment
asthma
patient
specif
ga
arggln
genotyp
carrier
lower
montelukast
concentr
gg
arg
group
one
month
lower
concentr
six
month
clinic
relev
allel
carrier
demonstr
benefit
montelukast
use
symptombas
score
research
replic
find
montelukast
absorpt
howev
anoth
studi
replic
find
fail
identifi
effect
polymorph
montelukast
plasma
concentr
albeit
differ
studi
design
involv
fewer
subject
studi
highlight
potenti
import
genet
factor
influenc
drug
transport
may
anticip
affect
pharmacokinet
pharmacodynam
similarli
sever
snp
anoth
transport
protein
multidrug
resist
protein
altern
name
atp
bind
cassett
subfamili
c
member
exampl
associ
montelukast
respons
chang
fev
predict
zileuton
respons
associ
potenti
confirm
pharmacogenet
signific
snp
marker
snp
intron
underli
function
mechan
includ
genet
variant
explain
effect
remain
resolv
overal
good
progress
pharmacogenet
leukotrien
modifi
therapi
asthma
snp
multipl
leukotrienesynthesis
enzym
eg
show
robust
associ
lta
ltsi
respons
multipl
gene
leukotrien
synthesi
pathway
andor
receptor
polymorph
associ
asthma
suscept
impli
may
leukotrienedriven
asthma
therefor
amen
treatment
ltsi
ltra
interest
drug
class
preliminari
data
suggest
signific
contribut
snp
drug
transport
gene
ultim
determin
pharmacokinet
pharmacodynam
data
set
scene
larger
prospect
studi
provid
accur
effect
size
determin
clinic
implic
greater
confid
corticosteroid
import
pharmacogenet
target
asthma
initi
investig
pharmacogenet
approach
corticosteroid
element
asthma
therapi
focus
glucocorticoid
receptor
gene
gr
altern
name
nuclear
receptor
subfamili
group
c
member
map
chromosom
region
region
associ
multipl
asthma
phenotyp
gene
discuss
chapter
sever
polymorph
describ
gr
gene
function
consequ
polymorph
shown
influenc
bind
affin
dexamethason
howev
similar
polymorph
shown
potenti
pharmacogenet
effect
sever
polymorph
rare
function
signific
question
despit
gr
remain
tantal
target
asthma
pharmacogenet
surpris
recent
investig
role
gr
polymorph
corticosteroid
respons
gr
gene
associ
geneticbas
varianc
corticosteroid
efficaci
asthma
treatment
number
gene
implic
includ
discuss
snp
corticotrophinreleas
hormon
receptor
gene
associ
respons
inhal
corticosteroid
treatment
base
end
point
chang
fev
follow
week
treatment
three
asthmat
cohort
use
candid
gene
approach
snp
gene
n
asthma
subject
exampl
intron
snp
exhibit
genotypespecif
chang
percentag
predict
chang
fev
respons
corticosteroid
therapi
adult
asthma
subject
studi
first
show
pharmacogenet
effect
steroid
efficaci
asthmat
cohort
highlight
gene
least
one
number
factor
determin
corticosteroid
efficaci
thought
influenc
respons
exogen
administ
corticosteroid
regul
endogen
level
corticosteroid
box
gene
shown
predictor
improv
bronchial
hyperrespons
bhr
year
chang
postcorticosteroid
treatment
children
base
genotypedepend
variat
nonsynonym
snp
presenc
g
allel
gave
greatest
improv
howev
associ
gene
remain
question
low
allel
frequenc
caucasian
maf
result
subject
n
avail
contribut
observ
addit
data
given
confid
involv
polymorph
significantli
associ
improv
asthma
control
presenc
corticosteroid
although
altern
allel
describ
associ
greater
control
korean
asthma
patient
week
treatment
interestingli
studi
ye
et
al
identifi
novel
gene
neurokinin
receptor
associ
improv
asthma
control
presenc
corticosteroid
g
allel
gli
snp
associ
greatest
improv
neurokinin
induc
bronchoconstrict
inflamm
therefor
modul
neurokinin
receptor
may
influenc
magnitud
respons
multipl
snp
stressinduc
phosphoprotein
gene
associ
variabl
fev
respons
treatment
inhal
corticosteroid
flunisolid
asthma
subject
studi
investig
snp
span
eight
candid
gene
identifi
snp
snp
affect
percent
chang
fev
respons
flunisolid
week
week
code
adaptor
protein
coordin
function
may
involv
format
glucocorticosteroid
receptor
heterocomplex
dualspecif
phosphatas
gene
encod
protein
dual
specif
tyrosin
threonin
inactiv
mitogenactiv
protein
kinas
mapk
recent
sever
snp
includ
region
snp
associ
bronchodil
respons
asthma
control
presenc
corticosteroid
cohort
asthma
patient
n
mechan
underli
effect
unclear
howev
suggest
corticosteroid
induc
express
may
alter
carrier
snp
influenc
abil
target
mapk
signal
pathway
cohort
asthmat
children
lowaffin
ige
receptor
gene
highlight
put
involv
corticosteroid
budesonid
regul
exacerb
virtu
associ
snp
intron
rel
risk
sever
exacerb
take
budesonid
interestingli
c
allel
also
associ
elev
ige
level
asthma
patient
importantli
pharmacogenet
associ
replic
two
asthma
cohort
n
respect
allel
associ
increas
hospit
visit
uncontrol
asthma
patient
receiv
ic
surpris
polymorph
variat
ige
receptor
influenc
receptor
express
alter
ige
level
associ
sever
form
asthma
turn
subject
adequ
control
corticosteroid
treatment
first
gwa
asthma
publish
identifi
snp
glucocorticoidinduc
transcript
gene
determin
glucocorticoid
respons
asthma
subject
studi
examin
snp
use
human
hap
beadchip
identifi
snp
interest
initi
cohort
parentchild
trio
primari
outcom
chang
fev
interest
snp
gene
promot
region
associ
attenu
fev
improv
postcorticosteroid
three
four
cohort
test
subsequ
gwa
identifi
tgene
novel
player
lung
function
respons
fev
inhal
corticosteroid
analys
carri
caucasian
asthmat
replic
secondari
asthmat
popul
n
success
replic
snp
associ
genet
model
direct
includ
top
snp
rank
p
valu
snp
strong
ld
variant
locat
tgene
suggest
gene
novel
player
pharmacogenet
regul
corticosteroid
efficaci
confirm
followup
associ
tgene
variant
associ
lung
function
respons
inhal
corticosteroid
initi
gwa
analysi
averag
increas
fev
respons
homozyg
wildtyp
subject
tt
cc
recent
develop
due
gwa
exampl
recent
hypothesisdriven
studi
implic
cytochrom
enzym
glucocorticosteroid
efficaci
modul
corticosteroid
metabol
studi
robert
et
al
show
mrnadriven
studi
confirm
via
microsom
recombin
enzym
metabol
corticosteroid
budesonid
inact
metabolit
suggest
differ
express
function
enzym
lung
andor
liver
could
influenc
corticosteroid
efficaci
treatment
asthma
date
major
pharmacogenet
studi
focus
one
class
asthma
therapi
howev
sever
recent
studi
investig
combin
therapi
accur
reflect
clinic
situat
summar
main
find
regard
influenc
polymorph
includ
combin
therapi
particularli
fluticasonesalmeterol
budesonideformoterol
section
howev
clear
report
associ
increas
exacerb
asthma
patient
use
regular
salbutamol
addit
mainten
combin
mix
studi
fail
report
associ
potenti
differ
studi
design
recent
addit
gene
investig
snp
associ
patient
respons
combin
therapi
studi
asthma
patient
regularli
use
icslaba
combin
shown
polymorph
nitrou
oxid
synthas
gene
involv
amino
acid
chang
associ
postdrug
improv
lung
function
chang
fev
pred
code
key
enzym
product
airway
f
e
shown
elev
asthma
consid
marker
ongo
inflamm
importantli
earlier
data
identifi
polymorph
function
influenc
level
f
e
tt
genotyp
associ
lower
f
e
level
data
suggest
lower
activ
potenti
lower
f
e
level
identifi
patient
like
respond
combin
therapi
howev
larger
prospect
trial
requir
valid
find
potenti
counterintuit
marker
inflamm
ic
target
inflamm
recent
studi
effect
genet
determin
snp
candid
gene
asthma
patient
respons
combin
fluticason
propionatesalmeterol
therapi
identifi
three
snp
cholinerg
muscarin
receptor
gene
associ
asthma
acq
score
found
singl
snp
heat
shock
protein
associ
chang
fev
interest
snp
also
associ
respons
lung
function
montelukast
see
earlier
suggest
tone
airway
determin
muscarin
receptor
import
therapi
target
airway
contract
involv
protein
fold
cell
import
note
snp
previous
associ
respons
ic
drug
develop
asthma
slow
gener
new
class
major
advanc
patient
care
come
new
compound
andor
indic
exist
drug
class
eg
improv
durat
action
laba
one
potenti
explan
limit
progress
design
recruit
phase
phase
ii
trial
evalu
new
compound
alreadi
outlin
initi
trial
demonstr
disappoint
effect
lung
function
asthma
symptom
care
select
patient
base
clinic
cellular
paramet
clinic
relev
improv
observ
research
understand
asthma
heterogen
particularli
strategi
target
specif
mediat
care
select
patient
necessari
fulli
understand
therapeut
potenti
new
drug
recent
approach
treatment
asthma
includ
follow
specif
target
singl
mediat
unlik
provid
therapeut
option
asthma
broadest
definit
howev
target
specif
subpopul
shown
clinic
efficaci
recent
studi
investig
human
monoclon
antibodi
tralokinumab
use
care
balanc
popul
atop
nonatop
asthmat
exclus
addit
respiratori
patholog
cigarett
smoke
packyear
recent
infect
treatment
immunosuppress
medic
random
doubleblind
studi
tralokinumab
associ
improv
lung
function
base
increas
fev
decreas
daili
adrenerg
receptoragonist
use
studi
overal
demonstr
care
select
asthma
subject
case
base
phenotyp
critic
asthma
drug
develop
novel
asthma
gene
identifi
paramount
evalu
potenti
drug
target
particularli
context
phase
ii
trial
take
account
pharmacogenet
factor
preliminari
data
support
genet
test
phase
ii
trial
newer
compound
shown
recent
report
dual
antagonist
pitrikinra
polymorph
variat
target
receptor
antagonist
ie
significantli
influenc
outcom
allerg
asthma
subject
pitrikinra
recombin
form
differ
two
amino
acid
residu
ie
mutein
shown
reduc
latephas
antigen
respons
lar
inhal
antigen
defin
chang
lung
function
fev
hour
postantigen
exposur
one
studi
subject
follow
fourweek
period
twice
daili
activ
treatment
nebul
pitrikinra
placebo
increas
lar
ratio
correl
reduc
fev
stratif
subject
pitrikinra
n
placebo
n
genotyp
group
nonsynonom
snp
identifi
argarg
carrier
attenu
lar
p
follow
pitrikinra
treatment
compar
glngln
glnarg
genotyp
similarli
stratif
base
show
attenu
lar
gluala
group
gluglu
group
interestingli
variant
combin
shown
risk
factor
allerg
asthma
lead
enhanc
signal
post
stimul
preliminari
data
suggest
select
subgroup
patient
particular
genotyp
anticip
receptorpathway
may
domin
role
individu
asthma
critic
interpret
phase
ii
clinic
trial
approach
defin
asthma
subphenotyp
eg
use
cluster
analys
use
confirm
heterogen
clinic
present
current
medic
extrem
success
asthma
manag
eg
ic
clear
individu
respons
medic
therapi
develop
heterogen
larg
variat
clinic
benefit
detriment
effect
stratif
asthma
treatment
use
clinic
andor
genet
approach
therefor
show
great
potenti
maxim
clinic
outcom
minim
advers
effect
lead
improv
manag
asthma
excel
progress
area
research
last
five
ten
year
introduct
antiig
omalizumab
therapi
mainstay
asthma
treatment
patient
clinic
indic
ie
sever
allerg
asthma
elev
serum
ige
level
stratif
prescrib
antiig
show
proofofconcept
target
expens
biolog
patient
like
show
clinic
benefit
similarli
accumul
evid
stratif
patient
phase
ii
trial
newer
therapiesfor
exampl
mepoluzimab
lebrikizumab
base
clinic
cellular
patient
profil
essenti
adequ
evalu
therapi
import
therapi
introduc
clinic
practic
clear
progress
asthma
pharmacogenet
come
complet
newer
studi
interrog
multipl
snp
larg
prospect
cohort
date
predominantli
candid
genepathway
approach
use
sever
genet
variant
identifi
confid
eg
leukotrien
modifi
respons
glucocorticoid
respons
importantli
studi
show
independ
replic
gold
standard
genet
studi
includ
specif
snp
direct
effect
also
importantli
sever
gwass
complet
provid
integr
common
variat
span
entir
genom
typic
test
snp
identifi
novel
gene
variant
hypothesisfre
approach
eg
collagen
locu
respons
albuterolsalbutamol
recent
find
still
need
replic
valid
howev
potenti
pave
way
respond
nonrespond
profil
base
multipl
snp
multipl
gene
measur
platform
key
question
rel
contribut
common
variat
measur
platform
rare
variat
current
measur
outcom
anoth
remain
question
relat
magnitud
chang
clinic
measur
genotyp
group
asthma
patient
eg
fev
data
far
suggest
differ
consid
clinic
relev
howev
work
larger
popul
requir
accur
estim
effect
size
similarli
genet
variat
identifi
date
account
modest
proport
overal
variat
trait
eg
recent
estim
suggest
heredit
bronchodil
respons
like
studi
far
confound
factor
includ
snphaplotyp
analys
genegen
interact
rel
contribut
snp
differ
ethnic
background
therefor
knowledg
dramat
increas
need
prospect
trial
current
compound
involv
larg
number
subject
hypothesisfre
approach
includ
gwa
gwa
approach
identifi
diseas
suscept
gene
miss
heredit
import
issu
pharmacogenet
studi
small
proport
heredit
current
assign
identifi
loci
eg
corticosteroid
respons
need
address
asthma
medic
success
person
unless
resolv
larger
degre
genet
variabl
andor
environment
factor
clinicalcellular
approach
stratifi
phase
ii
trial
newer
asthma
therapi
clear
genet
stratif
role
play
exampl
recent
phase
ii
trial
dual
antagonist
pitrikinra
suggest
patient
select
critic
evalu
clinic
efficaci
compound
specif
genotyp
identifi
respond
group
pharmacogenet
integr
requir
phase
ii
trial
repres
clear
challeng
drug
develop
pipelin
understand
genet
basi
asthma
increas
therapeut
target
asthma
becom
appar
eg
receptor
antagonist
clear
genet
variat
associ
asthma
suscept
gene
influenc
pathway
target
method
essenti
identifi
individu
pathway
may
particularli
import
also
like
exist
therapi
may
influenc
genet
factor
underli
asthma
suscept
particularli
therapi
multipl
target
eg
ic
impact
genet
knowledg
asthma
manag
prescrib
practic
limit
time
need
defin
complex
genet
basi
respond
advers
effect
larg
prospect
studi
howev
preliminari
reallif
studi
relat
outcom
measur
eg
day
school
provid
proof
concept
genet
inform
import
implic
diseas
manag
eg
inform
secondlin
therapi
asthma
use
remain
mani
unansw
question
regard
potenti
stratifi
approach
manag
asthma
progress
made
identifi
patient
subgroup
base
clinic
measur
cell
count
marker
express
work
requir
use
larg
studi
extens
character
asthma
patient
crosssect
also
longitudin
mani
year
identifi
natur
progress
diseas
field
genet
rapidli
progress
great
technolog
develop
move
dramat
pace
eg
gwa
compris
million
common
snp
sever
million
rare
snp
gene
express
studi
wholeexom
target
resequenc
approach
allow
interrog
genet
variat
effect
patient
subgroup
like
drugspecif
genet
profil
involv
sever
gene
eg
receptor
signal
mediat
transcript
factor
step
toward
person
medicin
asthma
associ
benefit
includ
avoid
advers
side
effect
adequ
control
diseas
anticip
approach
mani
novel
common
variantsgen
identifi
underli
respons
current
asthma
medic
cost
genet
analys
continu
fall
potenti
rel
simpl
test
impact
asthma
manag
cost
becom
real
possibl
genet
clinic
inform
go
influenc
clinic
practic
must
simpl
reproduc
diagnost
test
base
snp
combin
simpl
clinic
measur
adequ
high
specif
sensit
distinguish
respond
nonrespond
howev
introduct
routin
genet
andor
clinic
test
practic
requir
clear
demonstr
health
benefit
costeffect
outperform
current
stepwis
approach
asthma
manag
